Title: Addex Therapeutics Reports Q1 2026 Financial Results and Provides Corporate Update Date: June 25, 2026 Time: 16:00 CET (15:00 BST / 10:00 EDT / 07:00 PDT) ...

Geneva, Switzerland, June 25, 2026- Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

Addex Therapeutics' Phase 2 study missed statistical significance for patients to reach baseline seizure count for ADX71149 plus SoC. The company will complete the analysis and work with the partner ...

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 30, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...

Geneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only ...

Addex Therapeutics (ADXN) is scheduled to report earnings on November 22, 2024. The last reported earnings were for reported on September 30, 2024 for Q2.

Income decreased by CHF 0.3 million during the nine-month period ended September 30, 2025, compared to the same period ended September 30, 2024, primarily due to the completion of the R&D ...

Geneva, Switzerland, June 19, 2025-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...